Full-Time

Scientist

Analytical Development, Regeneron Cell Medicines

Updated on 9/4/2026

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceutical therapies for serious diseases

Compensation Overview

$93.9k - $153.3k/yr

Cambridge, MA, USA

In Person

On-site laboratory presence is required.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Biophysics
Data Analysis

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Requirements
  • A Bachelor's or Master's degree in Biophysics, Biochemistry, Molecular Biology, or a related field, with 6-8+ years of proven experience characterizing and quantitatively analyzing lentiviral vectors.
  • Ability to work independently to design experiments, interpret results, document findings, and communicate results.
  • Ability to prioritize effectively and drive work forward with minimal supervision.
Responsibilities
  • Advance analytical development for cell therapy programs, with a primary focus on lentiviral vectors.
  • Strengthen existing and establish new biophysical methods to characterize lentiviral vectors.
  • Analyze, interpret, and clearly present complex datasets to technical and cross-functional audiences.
  • Partner with cross-functional teams across Regeneron Cell Medicines to troubleshoot challenges, align on priorities, and support program execution.
  • Author and review technical documentation, including assay protocols, method development reports, and data summaries.
  • Maintain complete, timely, and compliant electronic lab notebook records.
  • Support instrument upkeep and independently troubleshoot equipment and assays.
  • Design and execute experiments and perform routine laboratory operations and instrument maintenance in an on-site laboratory setting.
Desired Qualifications
  • Experience with biophysical characterization techniques for sizing and counting particles, such as dynamic light scattering, microfluidic resistive pulse sensing, and fluorescent labeling assays.
  • Understanding and knowledge of viral vector biology, design, process, and gene delivery mechanisms.
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pasatru won FDA approval on August 19 2026 for adults with FOP.
  • Q2 2026 revenue rose 17% to $4.3 billion, driven by Dupixent and EYLEA HD.
  • U.S. EYLEA HD sales jumped 52% in Q2 2026 to $596 million.

What critics are saying

  • The May 15 2026 fianlimab melanoma failure triggered a class action by September 14.
  • Roche’s Vabysmo keeps pressuring EYLEA, and U.S. EYLEA sales fell 45% in Q2 2026.
  • Another late-stage oncology miss would crush Regeneron’s pipeline premium and investor trust.

What makes Regeneron Pharmaceuticals unique

  • Regeneron’s antibody discovery engine repeatedly produces homegrown drugs and partners.
  • Sanofi’s Dupixent collaboration funds Regeneron without requiring full commercial burden.
  • EYLEA HD protects the eye franchise through higher dosing convenience and conversion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

10%

2 year growth

10%
Yahoo Finance
Sep 9th, 2026
EYLEA franchise hits $5.97B in US sales as EYLEA HD drives 29% growth

Regeneron Pharmaceuticals' EYLEA franchise generated approximately $5.97 billion in US sales during 2024, according to a new market analysis report covering major pharmaceutical markets through 2034. The ophthalmology treatment addresses serious retinal diseases including neovascular age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Standard-dose EYLEA contributed approximately $4.77 billion in US sales during 2024. EYLEA HD, the 8mg formulation approved in 2023, generated approximately $1.2 billion in US sales during 2024. The higher-dose version supports longer treatment intervals for eligible patients, potentially reducing injection frequency compared with standard anti-VEGF dosing schedules. The report, added to ResearchAndMarkets.com's catalogue, covers seven major pharmaceutical markets including the United States, Germany, France, Italy, Spain, the United Kingdom and Japan, with historical analysis from 2020 and forecasts through 2034.

MarketBeat
Sep 6th, 2026
Nilsine Partners LLC makes new investment in Veeva Systems Inc. $VEEV.

Nilsine Partners LLC makes new investment in Veeva Systems Inc. $VEEV. September 6, 2026 Key points. * Nilsine Partners initiated a position in Veeva Systems during the second quarter, purchasing 14,995 shares valued at approximately $2.66 million. Institutional investors and hedge funds collectively own 88.2% of the company. * Veeva reported strong quarterly results, with revenue rising 17.6% year over year to $927.96 million and EPS of $2.35 surpassing estimates. The company also raised its fiscal 2027 outlook, supported by Vault CRM migrations and growing AI adoption. * Analyst sentiment remains favorable, with a "Moderate Buy" consensus and an average price target of $284.46, although Veeva's premium valuation and recent insider selling remain considerations for investors. * MarketBeat previews top five stocks to own in October. Nilsine Partners LLC acquired a new position in shares of Veeva Systems Inc. (NYSE:VEEV - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 14,995 shares of the technology company's stock, valued at approximately $2,661,000. Other large investors have also modified their holdings of the company. Williams Jones Wealth Management LLC. boosted its holdings in Veeva Systems by 0.4% in the 3rd quarter. Williams Jones Wealth Management LLC. now owns 9,419 shares of the technology company's stock worth $2,806,000 after acquiring an additional 40 shares during the period. Rafferty Asset Management LLC increased its stake in Veeva Systems by 0.7% during the 2nd quarter. Rafferty Asset Management LLC now owns 6,881 shares of the technology company's stock worth $1,982,000 after buying an additional 51 shares during the period. Brown Brothers Harriman & Co. lifted its holdings in Veeva Systems by 8.1% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 719 shares of the technology company's stock worth $214,000 after buying an additional 54 shares in the last quarter. Main Management ETF Advisors LLC boosted its position in Veeva Systems by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 5,481 shares of the technology company's stock valued at $1,224,000 after buying an additional 56 shares during the last quarter. Finally, Root Financial Partners LLC boosted its position in Veeva Systems by 17.1% in the 4th quarter. Root Financial Partners LLC now owns 383 shares of the technology company's stock valued at $85,000 after buying an additional 56 shares during the last quarter. Institutional investors and hedge funds own 88.20% of the company's stock. Here are the key news stories impacting Veeva Systems this week: * Higher outlook and strong operating momentum: Veeva raised its fiscal 2027 outlook as Vault CRM migrations, research-and-development investment and Falcon AI adoption support revenue growth and expanding profitability. This follows a strong latest quarter, in which revenue increased 17.6% year over year to approximately $928 million and adjusted earnings exceeded analyst expectations. * AI adoption is broadening: Regeneron and Biogen have adopted Veeva's AI-powered Vault CRM suite globally. Veeva also introduced Falcon Safety, an agentic AI product designed for biopharmaceutical safety operations. These developments could deepen customer relationships and expand Veeva's role in commercial and safety workflows. * Long-term investor support: Commentary highlights Veeva's recurring-revenue model, Vault CRM migration opportunity and AI expansion as reasons the stock remains attractive for long-term growth investors. Investor Michael Burry has also reportedly remained bullish on Veeva while criticizing Snowflake's valuation. * Valuation and competition remain important considerations: Analysts and portfolio commentary generally support holding VEEV, but warn that market saturation could limit future growth. With the stock trading at a premium earnings multiple after a substantial rally, investors may require continued execution and strong guidance upgrades. * Insider selling may weigh modestly on sentiment: Veeva's exiting president sold 10,000 shares for approximately $2.8 million, representing about 51% of the executive's direct equity stake before the transaction. The sale does not establish a change in business fundamentals, but it can raise caution after the stock's strong advance. Analyst ratings changes. Several research analysts recently commented on VEEV shares. Royal Bank Of Canada boosted their price target on Veeva Systems from $275.00 to $325.00 and gave the stock an "outperform" rating in a research note on Thursday, August 27th. TD Cowen raised their price objective on Veeva Systems from $235.00 to $283.00 and gave the company a "buy" rating in a research note on Monday, August 24th. Citigroup upped their target price on Veeva Systems from $190.00 to $273.00 and gave the company a "neutral" rating in a research report on Friday, August 28th. Zacks Research cut Veeva Systems from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 14th. Finally, Needham & Company LLC raised their price target on shares of Veeva Systems from $270.00 to $310.00 and gave the stock a "buy" rating in a research report on Thursday, August 27th. Nineteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Veeva Systems presently has an average rating of "Moderate Buy" and an average price target of $284.46. Discover more Premium stock reports Stocks & Bonds Veeva Systems stock down 3.6%. Shares of Veeva Systems stock opened at $274.02 on Friday. The business has a 50-day moving average price of $220.49 and a 200 day moving average price of $187.95. Veeva Systems Inc. has a fifty-two week low of $148.05 and a fifty-two week high of $310.50. The firm has a market cap of $44.51 billion, a P/E ratio of 45.07, a P/E/G ratio of 1.17 and a beta of 0.97. Veeva Systems (NYSE:VEEV - Get Free Report) last released its earnings results on Wednesday, August 26th. The technology company reported $2.35 EPS for the quarter, topping analysts' consensus estimates of $2.23 by $0.12. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%.The company had revenue of $927.96 million for the quarter, compared to the consensus estimate of $905.38 million. During the same quarter last year, the business posted $1.99 EPS. Veeva Systems's quarterly revenue was up 17.6% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. As a group, equities research analysts anticipate that Veeva Systems Inc. will post 6.7 earnings per share for the current year. Insiders place their bets. In other Veeva Systems news, insider Thomas Schwenger sold 10,000 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $281.33, for a total transaction of $2,813,300.00. Following the sale, the insider directly owned 19,449 shares of the company's stock, valued at approximately $5,471,587.17. This represents a 33.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.60% of the stock is currently owned by insiders. Veeva Systems company profile. Veeva Systems NYSE: VEEV is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint. Veeva's product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Veeva Systems, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veeva Systems wasn't on the list. While Veeva Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

ABNewswire
Sep 5th, 2026
Food Allergy Clinical trial pipeline: emerging therapies and key developments shaping the treatment landscape | DelveInsight.

Food Allergy Clinical trial pipeline: emerging therapies and key developments shaping the treatment landscape | DelveInsight. Posted on September 5, 2026. The Food Allergy clinical trial analysis report delivers important insights into ongoing research of 25+ pipeline Food Allergy drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, New York, USA) September 05, 2026- DelveInsight's "Food Allergy Pipeline Insight 2026" report provides comprehensive insights into 25+ companies and 30+ pipeline drugs in the Food Allergy pipeline landscape. It covers the Food Allergy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Food Allergy Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Food Allergy Pipeline Report * On September 02, 2026, Novartis Pharmaceuticals initiated a Phase III study is to evaluate the clinical efficacy and safety of remibrutinib in participants with peanut, or cow's milk ("milk", cooked and uncooked) or hen's egg ("egg", cooked and uncooked) immunoglobulin E (IgE)- mediated allergy in comparison to placebo. * On August 20, 2026, Regeneron Pharmaceuticals conducted a study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment. * DelveInsight's Food Allergy Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Food Allergy treatment. * The leading Food Allergy Companies include DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune, and others. * Promising Food Allergy Therapies such as Omalizumab, Acalabrutinib, Neffy, Adrenaline, RPT904, Montelukast, Remibrutinib, and others. Want to know which companies are leading innovation in Food Allergy? @ Food Allergy Clinical Trials Assessment The Food Allergy Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Food Allergy Pipeline Report also highlights the unmet needs with respect to food allergy. Food Allergy Overview Food allergies are adverse health effects resulting from a specific immune response that occurs reproducibly on exposure to a given food. These immune responses can range from mild to severe, potentially affecting the skin, gastrointestinal tract, respiratory, and cardiovascular systems. Food allergies are distinct from food intolerances, which do not involve the immune system and are generally less severe. The prevalence of food allergies has been rising, especially in developed countries, with an estimated 5-8% of children and 1-2% of adults affected worldwide. Food Allergy Emerging Drugs Profile * Viaskin Peanut: DBV Technologies Viaskin Peanut (DBV712) is the novel product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system through the skin. Viaskin is based on epicutaneous immunotherapy, or EPIT(R), DBV's method of delivering biologically active compounds to the immune system through intact skin. The Viaskin patch contains a deposit of dry allergen at its center that sits above the skin on a backing film. When the patch is applied to intact skin, a condensation chamber is formed between the allergen and the top layer of skin, the epidermis. Natural water loss from the skin accumulates within the condensation chamber, solubilizing the allergen. The drug is currently being investigated in the Registration stage of development for the treatment of peanut allergy. * PVX-108: Aravax PVX108 is a next-generation, allergen-specific immunotherapy using peptides that represent critical fragments of peanut proteins to precisely target the T cells driving peanut allergy. Administered once per month, therapy is designed to precisely induce tolerance to peanut protein without the safety concerns constraining the use of the only registered therapy which uses natural extracts from peanuts. The presence of whole peanut allergens in those extracts exposes patients to significant risks of anaphylaxis. Previously, a randomized, double-blind, placebo-controlled Phase I trial in 66 peanut-allergic adults (AVX-001) showed no evidence of adverse events of clinical concern. Additionally, ex vivo studies providing a surrogate measure of safety (basophil activation) in 185 peanut-allergic blood donors confirmed a lack of basophil reactivity to PVX108 in contrast to peanut extract. These data demonstrate that PVX108 has a highly favorable safety profile for treatment of peanut allergic patients, including those with severe allergy. The drug is currently being investigated in the Phase II stage of development for the treatment of peanut allergy. * INT301: Intrommune Therapeutics INT301 is an investigational oral mucosal immunotherapy (OMIT) product developed by Intrommune Therapeutics for the treatment of peanut allergy. It is a toothpaste-based formulation designed for daily use, delivering allergen proteins directly to the immune system via the oral mucosa to induce desensitization. Unlike traditional oral immunotherapy (OIT), INT301 aims to reduce allergic reactions with improved safety and convenience. The product is currently in clinical development. The drug is currently being investigated in the Phase I stage of development for the treatment of peanut allergy. The Food Allergy Pipeline report provides insights into:- * The report provides detailed insights about companies that are developing therapies for the treatment of Food Allergy with aggregate therapies developed by each company for the same. * It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Food Allergy Treatment. * Food Allergy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. * Food Allergy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. * Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Food Allergy market. Food Allergy Companies DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune and others. Food Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as * Intravenous * Subcutaneous * Oral * Intramuscular Food Allergy Products have been categorized under various Molecule types such as * Monoclonal antibody * Small molecule * Peptide From emerging drug candidates to competitive intelligence, the Food Allergy Pipeline Report covers it all @ Food Allergy Market Drivers and Barriers, and Future Perspectives Scope of the Food Allergy Pipeline Report * Coverage- Global * Food Allergy Companies- DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune and others. * Food Allergy Therapies- Omalizumab, Acalabrutinib, Neffy, Adrenaline, RPT904, Montelukast, Remibrutinib and others. * Food Allergy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination * Food Allergy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Discover what's next for the Food Allergy Treatment landscape in this detailed analysis @ Food Allergy Emerging Drugs and Major Players Table of Contents * Introduction * Executive Summary * Food Allergy: Overview * Pipeline Therapeutics * Therapeutic Assessment * Food Allergy- DelveInsight's Analytical Perspective * Late Stage Products (Preregistration) * Viaskin Peanut: DBV Technologies * Mid Stage Products (Phase II) * PVX-108: Aravax * Early Stage Products (Phase I) * INT301: Intrommune Therapeutics * Drug profiles in the detailed report... * Preclinical and Discovery Stage Products * Drug Name: Company Name * Inactive Products * Food Allergy Key Companies * Food Allergy Key Products * Food Allergy- Unmet Needs * Food Allergy- Market Drivers and Barriers * Food Allergy- Future Perspectives and Conclusion * Food Allergy Analyst Views * Food Allergy Key Companies * Appendix DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, AB Newswire offer customized research solutions and insights to clients across the globe. Connect with AB Newswire to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/report-store/food-allergy-pipeline-insight

AD HOC NEWS
Sep 4th, 2026
Regeneron stock trades lower as insider sales and lawsuit weigh on sentiment.

Regeneron stock trades lower as insider sales and lawsuit weigh on sentiment. Published on 09/04/2026 at 14:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Regeneron stock is trading below recent highs as new insider selling disclosures and a fresh securities class action highlight ongoing fallout from a failed melanoma trial, while analysts still see upside based on strong recent earnings. Regeneron Pharmaceuticals stock (ISIN US75886F1075) is changing hands around 843.47 USD as of September 4, 2026, down about 1.0% from the prior close and noticeably below levels above 850 USD seen earlier this week according to recent market data compiled by MarketBeat. Insider sales add pressure after prior price drop. A fresh catalyst for the Regeneron stock narrative comes from newly reported insider transactions filed with the U.S. Securities and Exchange Commission on September 3, 2026. According to a Form 4 summary compiled by StockTitan, Regeneron executive vice president Marion McCourt sold 1,131 shares of company stock at 857.39 USD per share on September 3, 2026, following a sale of 1,215 shares at 850.00 USD per share on September 2, 2026. In a separate filing summarized by StockTitan, a Regeneron director exercised options for 400 shares at an exercise price of 719.37 USD per share and sold the same 400 shares at 850.00 USD per share on September 2, 2026 under a pre-arranged Rule 10b5-1 trading plan. For investors, these insider sales at prices in the 850 to 857 USD range underline how the current 843.47 USD trading level sits slightly below the levels insiders were recently able to realize. Class action lawsuit follows failed melanoma trial. The backdrop to the current sentiment around Regeneron stock includes a newly highlighted securities class action related to a failed Phase 3 melanoma trial. As reported in an investor alert by Hagens Berman Sobol Shapiro on September 3, 2026, the law firm has filed a securities fraud class action against Regeneron after surprising revelations about the protocol and ultimate failure of a Phase 3 clinical trial for a melanoma therapy. The alert notes that news of the trial failure previously drove Regeneron shares sharply lower, erasing about 11 billion USD in market capitalization and prompting the lawsuit, which seeks to represent investors who bought Regeneron common stock between August 1, 2025 and May 15, 2026. A separate investor notice summarized by Morningstar states that Regeneron shares fell approximately 13.95%, or 102.09 USD per share, from a closing price of 731.77 USD on April 28, 2026 to 629.68 USD on May 18, 2026 following the alleged corrective disclosures. More background on Regeneron stock. Regeneron is a major U.S. biotechnology company with a broad pipeline in immunology and oncology; the dedicated topic page offers additional news, figures and filings for investors tracking the stock. Analyst consensus still points to upside. Despite the legal overhang, recent data show that the analyst community remains broadly constructive on Regeneron stock. According to an overview published by MarketBeat on September 4, 2026, the company currently has a consensus rating of Moderate Buy and a consensus price target of 800.36 USD per share based on aggregated analyst estimates. The same MarketBeat summary notes that Regeneron Pharmaceuticals shares opened at 843.47 USD on the referenced trading day, implying that the consensus price target of 800.36 USD sits modestly below the current market level. The narrow gap between the 843.47 USD opening price and the 800.36 USD analyst target highlights a relatively balanced view: analysts see fundamental support but only limited additional upside from today's price, especially after the stock's recovery from the May 2026 low of 629.68 USD cited in the class action notice. Representative therapy from Regeneron portfolio. Regeneron Pharmaceuticals is best known to many patients and physicians for its injectable biologic treatments, which target immune pathways in conditions ranging from eye disease to inflammatory disorders. A key representative product is the company's monoclonal antibody therapies used in oncology and immunology, which rely on Regeneron's proprietary technology platforms to generate and optimize candidate antibodies for clinical development. Regeneron stock price and investor perspective. Based on recent market snapshots reported by MarketBeat and other stock portals as of September 4, 2026, Regeneron stock is trading around 843.47 USD on the Nasdaq, with intraday moves that have kept it within a range just below the 850 USD levels where insiders recently sold part of their holdings. For investors, the combination of prior sharp declines linked to the failed melanoma trial, current insider sales at slightly higher prices, and a consensus analyst target of 800.36 USD frames Regeneron as a large-cap biotechnology name where legal and pipeline risks now sit alongside solid earnings and a still supportive, but cautious, analyst view. Regeneron stock facts. * Company: Regeneron Pharmaceuticals Inc. * ISIN: US75886F1075 * Ticker: REGN * Trading venue: NASDAQ * Price (as of September 4, 2026): 843.47 USD * Market capitalization: tens of billions USD (as of September 4, 2026) * Sector / Industry: Biotechnology / Pharmaceuticals * Index membership: S&P 500 Further coverage and discussions. Sponsored Ad Regeneron stock: new analysis - 5 September. Fresh Regeneron information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US75886F1075 | REGENERON | boerse | 70054454 | bgmi

HR TODAY
Sep 4th, 2026
Regeneron appoints Suzan Vulaj as Vice President, Global Talent Acquisition.

Regeneron appoints Suzan Vulaj as Vice President, Global Talent Acquisition. New York, United States, September 2026 - Regeneron has appointed Suzan Vulaj as Vice President, Global Talent Acquisition. Vulaj brings more than 20 years of experience across talent acquisition, internal mobility, HR business partnering and recruiting, with leadership experience spanning media and entertainment, technology, financial services and global commerce. Vulaj joins Regeneron after more than nine years with NBCUniversal, where she progressed through increasingly senior talent acquisition leadership roles. Most recently, she served as Senior Vice President, Global Talent Acquisition, after previously holding the position of Vice President, Global Talent Acquisition for more than four years. Earlier in her NBCUniversal tenure, she was Director, Talent Acquisition - Operations and Technology, supporting recruiting priorities across key operational and technology functions. Before NBCUniversal, Vulaj spent three years with Pitney Bowes as Director, Global Talent Acquisition - Software, Global eCommerce and Innovation Engineering. In that role, she led talent acquisition across technology-oriented and innovation-focused areas, building on her experience in recruiting for specialized and business-critical functions. Earlier, Vulaj spent eight years with McGraw Hill Financial, where her career spanned recruiting, HR and internal mobility. She served as Senior Talent Manager - Internal Mobility, helping facilitate cross-functional employee movement through promotions, transfers, assignments and succession planning. Prior to that, she was HR Manager for Finance, Information Technology, Data Strategy & Operations, and the Program Management Office, following more than four years as a Senior Staffing Consultant. Vulaj began her earlier recruiting career with Google, where she worked as a Recruiting Coordinator from 2005 to 2006. Across her career, she has built broad expertise in global talent acquisition, workforce mobility, recruiting operations, technology hiring and talent strategy across large and complex organizations. She earned a BBA in Business Management from Pace University's Lubin School of Business, with a concentration in Human Resource Management and a minor in Economics. Her combination of global talent acquisition leadership and HR experience provides a strong foundation for her new role supporting Regeneron's continued growth and talent strategy. Regeneron is a biopharmaceutical company focused on inventing, developing and commercializing medicines for people with serious diseases. The company operates across a global network and integrates scientific research, manufacturing and commercialization to advance new therapies. Regeneron's approach centers on bringing together scientific ideas and multidisciplinary teams to create meaningful advances in healthcare while continuing to expand its capabilities across research, development and commercialization.